Thrombophilia Global Market Size, Share, By Type, By Diagnosis, By Treatment, Opportunity Analysis and Industry Forecast, 2024-2033 | Pfizer Inc., Novartis AG, Sanofi SA, Siemens

Spread the love

The Thrombophilia by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Thrombophilia Market:
https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

According to The Business Research Company’s Thrombophilia, the thrombophilia market size has grown strongly in recent years. It will grow from $15.97 billion in 2023 to $17.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing awareness, research and development in anticoagulant therapies, aging population, genetic research, increased incidence of thrombotic disorders.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $23.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine, emergence of novel therapies, integration of artificial intelligence, healthcare policy and regulation, increased patient education and empowerment. Major trends in the forecast period include technological advancements, expanded role of telemedicine, rising incidence rates, biopharmaceutical developments, collaborative research initiatives.

An increase in the elderly population is expected to propel the growth of the thrombophilia market going forward. The elderly population refers to those aged 65 and up, with the proportion of the dependent population determined as the total elderly and youth population expressed as a ratio of the total population. Thrombophilic risk factors are common in elderly adults and allow for the identification of a population at risk for poor clinical outcomes, hence, the rise in the elderly population will boost the market as it creates demand for thrombophilia drugs. For instance, according to the data released by America’s Health Rankings, a US-based organization that evaluates health outcomes, in 2022, more than 56 million adults aged 65 and older account for around 16.9% of the total US population. More than 73.1 million older people are expected by 2030, when the last of the baby boomer generation enters old age. Therefore, the increase in the elderly population is driving the growth of the thrombophilia market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9439&type=smp

The thrombophilia market covered in this report is segmented –
1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
2) By Drugs: Heparin, Warfarin, Other Drugs
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End-Users: Hospitals, Homecare, Speciality Centres, Other End Users

Technological advancements are the key trend gaining popularity in the thrombophilia market. Major companies operating in the market are developing innovative technologies to sustain their position in the market. For instance, in 2021, the University of Oslo, a Norway-based public research university, created a brand-new technology known as super albumin that may result in the creation of long-acting drugs and have important consequences for people who suffer from hemophilia, a condition that damages the blood’s capacity to clot. The university’s research group developed a cutting-edge biomedical technique that can be utilized to produce coagulation factors with a significantly longer half-life than those that are available at present. The starting point is a detailed investigation of a biological mechanism. They were able to produce super albumin, a protein variant that can be coupled with protein-based drugs to extend their bloodstream half-life, using the knowledge they gained from this research.

The thrombophilia market report table of contents includes:
1. Executive Summary